Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2005 1
2007 2
2008 1
2009 1
2010 1
2011 3
2013 2
2014 4
2015 5
2016 2
2017 1
2018 2
2019 4
2020 7
2021 10
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

44 results
Results by year
Filters applied: . Clear all
Page 1
A decade of LARP society.
Blagden SP, Bayfield M, Bousquet-Antonelli C. Blagden SP, et al. RNA Biol. 2021 Feb;18(2):157-158. doi: 10.1080/15476286.2020.1755505. RNA Biol. 2021. PMID: 33651971 Free PMC article. No abstract available.
The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial.
Schwenzer H, De Zan E, Elshani M, van Stiphout R, Kudsy M, Morris J, Ferrari V, Um IH, Chettle J, Kazmi F, Campo L, Easton A, Nijman S, Serpi M, Symeonides S, Plummer R, Harrison DJ, Bond G, Blagden SP. Schwenzer H, et al. Among authors: blagden sp. Clin Cancer Res. 2021 Dec 1;27(23):6500-6513. doi: 10.1158/1078-0432.CCR-21-1652. Epub 2021 Sep 8. Clin Cancer Res. 2021. PMID: 34497073
Controversies around the function of LARP1.
Berman AJ, Thoreen CC, Dedeic Z, Chettle J, Roux PP, Blagden SP. Berman AJ, et al. Among authors: blagden sp. RNA Biol. 2021 Feb;18(2):207-217. doi: 10.1080/15476286.2020.1733787. Epub 2020 Apr 1. RNA Biol. 2021. PMID: 32233986 Free PMC article. Review.
LARP1 isoform expression in human cancer cell lines.
Schwenzer H, Abdel Mouti M, Neubert P, Morris J, Stockton J, Bonham S, Fellermeyer M, Chettle J, Fischer R, Beggs AD, Blagden SP. Schwenzer H, et al. Among authors: blagden sp. RNA Biol. 2021 Feb;18(2):237-247. doi: 10.1080/15476286.2020.1744320. Epub 2020 Apr 14. RNA Biol. 2021. PMID: 32286153 Free PMC article.
The perfect arrangement.
Blagden SP. Blagden SP. J Clin Oncol. 2014 Feb 20;32(6):601-2. doi: 10.1200/JCO.2013.54.3405. Epub 2014 Jan 21. J Clin Oncol. 2014. PMID: 24449242 No abstract available.
Effective delivery of Complex Innovative Design (CID) cancer trials-A consensus statement.
Blagden SP, Billingham L, Brown LC, Buckland SW, Cooper AM, Ellis S, Fisher W, Hughes H, Keatley DA, Maignen FM, Morozov A, Navaie W, Pearson S, Shaaban A, Wydenbach K, Kearns PR; Experimental Cancer Medicine Centres (ECMC) CID trials working group. Blagden SP, et al. Br J Cancer. 2020 Feb;122(4):473-482. doi: 10.1038/s41416-019-0653-9. Epub 2020 Jan 6. Br J Cancer. 2020. PMID: 31907370 Free PMC article. Review.
Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cells.
Artibani M, Masuda K, Hu Z, Rauher PC, Mallett G, Wietek N, Morotti M, Chong K, KaramiNejadRanjbar M, Zois CE, Dhar S, El-Sahhar S, Campo L, Blagden SP, Damato S, Pathiraja PN, Nicum S, Gleeson F, Laios A, Alsaadi A, Santana Gonzalez L, Motohara T, Albukhari A, Lu Z, Bast RC Jr, Harris AL, Ejsing CS, Klemm RW, Yau C, Sauka-Spengler T, Ahmed AA. Artibani M, et al. Among authors: blagden sp. JCI Insight. 2021 Jun 8;6(11):e147929. doi: 10.1172/jci.insight.147929. JCI Insight. 2021. PMID: 33945502 Free PMC article.
44 results